See more : Clasquin SA (ALCLA.PA) Income Statement Analysis – Financial Results
Complete financial analysis of Arcturus Therapeutics Holdings Inc. (ARCT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Arcturus Therapeutics Holdings Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Tremor International Ltd (TRMR) Income Statement Analysis – Financial Results
- NextSource Materials Inc. (NSRCF) Income Statement Analysis – Financial Results
- Investeringsforeningen Investin – K Invest High Yield Obligationer (WEIJHO.CO) Income Statement Analysis – Financial Results
- Investor AB (publ) (IVSXF) Income Statement Analysis – Financial Results
- Alabama Power Company (APRDM) Income Statement Analysis – Financial Results
Arcturus Therapeutics Holdings Inc. (ARCT)
About Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 157.75M | 205.76M | 12.36M | 9.54M | 20.79M | 15.75M | 13.00M | 20.38M | 6.14M | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 2.96M | 143.05M | 171.86M | 55.95M | 32.44M | 16.98M | 410.00K | 294.00K | 51.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 154.79M | 62.70M | -159.50M | -46.41M | -11.65M | -1.23M | 12.59M | 20.09M | 6.09M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 98.13% | 30.48% | -1,290.57% | -486.50% | -56.04% | -7.80% | 96.85% | 98.56% | 99.17% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 192.13M | 147.75M | 173.76M | 57.85M | 33.64M | 16.98M | 15.92M | 18.39M | 13.46M | 25.11M | 7.07M | 818.00K | 1.82M |
| General & Administrative | 52.87M | 46.07M | 41.45M | 23.22M | 12.66M | 20.58M | 7.57M | 5.36M | 4.99M | 5.84M | 3.22M | 683.00K | 2.08M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 52.87M | 46.07M | 41.45M | 23.22M | 12.66M | 20.58M | 7.57M | 5.36M | 4.99M | 5.84M | 3.22M | 683.00K | 2.08M |
| Other Expenses | 0.00 | -244.00K | 0.00 | 0.00 | 0.00 | 0.00 | -348.00K | 1.42M | 1.25M | 2.13M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 235.95M | 193.58M | 215.21M | 81.06M | 46.30M | 37.56M | 23.49M | 25.17M | 19.70M | 33.08M | 10.29M | 1.50M | 3.91M |
| Cost & Expenses | 245.00M | 193.58M | 215.21M | 81.06M | 46.30M | 37.56M | 23.49M | 25.17M | 19.70M | 33.08M | 10.29M | 1.50M | 3.91M |
| Interest Income | 17.36M | 2.58M | 753.00K | 470.00K | 408.00K | 514.00K | 89.00K | 798.00K | 338.00K | 239.00K | 22.00K | 2.00K | 21.00K |
| Interest Expense | 767.00K | 420.00K | 2.67M | 361.00K | 446.00K | 186.00K | 150.00K | 295.00K | 251.00K | 2.00K | 197.00K | 80.00K | 44.00K |
| Depreciation & Amortization | 2.96M | 1.53M | 1.19M | 882.00K | 684.00K | 582.00K | 410.00K | 294.00K | 51.00K | 31.00K | 8.00K | 7.00K | 6.00K |
| EBITDA | -24.17M | 13.70M | -201.66M | -70.64M | -24.42M | -20.72M | -10.34M | -947.00K | -1.72M | -32.81M | -10.28M | -1.51M | -3.92M |
| EBITDA Ratio | -15.32% | 5.67% | -1,621.42% | -752.56% | -122.88% | -133.42% | -79.56% | -123.18% | -320.09% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -78.21M | 12.18M | -202.85M | -71.52M | -25.51M | -21.81M | -10.49M | -25.17M | -19.70M | -33.08M | -10.29M | -1.50M | -3.91M |
| Operating Income Ratio | -49.58% | 5.92% | -1,641.33% | -749.81% | -122.72% | -138.46% | -80.72% | -123.48% | -320.92% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 50.32M | -1.53M | -822.00K | -624.00K | -478.00K | 26.00K | -409.00K | -536.00K | 11.00K | 227.00K | -197.00K | -78.00K | -23.00K |
| Income Before Tax | -27.89M | 10.64M | -203.67M | -72.15M | -25.99M | -21.79M | -10.90M | -24.53M | -19.40M | -32.85M | -10.49M | -1.58M | -3.93M |
| Income Before Tax Ratio | -17.68% | 5.17% | -1,647.98% | -756.35% | -125.02% | -138.29% | -83.87% | -120.35% | -316.03% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 1.84M | 1.30M | 3.19M | -784.00K | -270.00K | 212.00K | 1.00K | 73.00K | 51.00K | -17.00K | 61.00K | 65.00K | 21.00K |
| Net Income | -29.73M | 9.35M | -206.86M | -71.36M | -25.72M | -21.79M | -10.90M | -24.60M | -19.45M | -32.83M | -10.55M | -1.58M | -3.93M |
| Net Income Ratio | -18.84% | 4.54% | -1,673.78% | -748.13% | -123.72% | -138.29% | -83.87% | -120.71% | -316.86% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.12 | 0.35 | -7.86 | -3.51 | -2.13 | -2.16 | -3.53 | -6.25 | -6.29 | -16.81 | -7.25 | -0.99 | -2.47 |
| EPS Diluted | -1.12 | 0.35 | -7.86 | -3.51 | -2.13 | -2.16 | -3.53 | -6.25 | -6.29 | -16.81 | -7.25 | -0.99 | -2.47 |
| Weighted Avg Shares Out | 26.63M | 26.45M | 26.32M | 20.31M | 12.07M | 10.07M | 3.09M | 3.94M | 3.09M | 1.95M | 1.45M | 1.59M | 1.59M |
| Weighted Avg Shares Out (Dil) | 26.63M | 27.09M | 26.32M | 20.31M | 12.07M | 10.07M | 3.09M | 3.94M | 3.09M | 1.95M | 1.45M | 1.59M | 1.59M |
Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination
Here's Why Investors Should Invest in Arcturus Stock Now
New Strong Buy Stocks for September 13th
Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics' Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma
Does Arcturus Therapeutics (ARCT) Have the Potential to Rally 216.35% as Wall Street Analysts Expect?
What Makes Arcturus Therapeutics (ARCT) a New Strong Buy Stock
New Strong Buy Stocks for August 23rd
High-Risk, High-Reward: Arcturus Nears Commercialization Of Kostaive Vaccine
Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2024 Earnings Call Transcript
Arcturus Therapeutics (ARCT) Reports Q2 Loss, Tops Revenue Estimates
Source: https://incomestatements.info
Category: Stock Reports